Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Rheumatology

Building Your Care Team and Preparing for Visits

At a Glance

For TRAPS, a rheumatologist or immunologist with autoinflammatory expertise can coordinate care, while genetic, kidney, and other specialists may join as needed. Bring the complete genetic report, flare diary, inflammation labs, and family history to each visit.

Because Tumor Necrosis Factor Receptor 1 Associated Periodic Syndrome (TRAPS) is an exceptionally rare condition, assembling the right care team is vital. Current consensus guidelines emphasize a multidisciplinary approach—meaning experts from different fields working together to manage your symptoms and protect your long-term health [1][2].

Selecting Your Care Team

Your care should be centered around a specialist with rare-disease expertise:

  • The Autoinflammatory Expert (Rheumatologist or Immunologist): This specialist usually coordinates your care. They should have experience managing systemic autoinflammatory diseases and be comfortable prescribing, monitoring, and navigating insurance authorization for IL-1 inhibitors [2][3].
  • The Genetic Counselor / Medical Geneticist: TRAPS is a complex genetic condition. A genetic counselor can help interpret your TNFRSF1A variant (especially if it is a Variant of Uncertain Significance), discuss inheritance patterns, and guide family planning [4][5].
  • The Nephrologist (Kidney Specialist): While not every patient needs to see a nephrologist immediately, they become a crucial referral if you have proteinuria (protein in the urine), reduced kidney function, hypertension, or are at high risk for AA amyloidosis [6][7].

In some cases, you may also need a cardiologist (if you experience chest pain or heart lining inflammation) or an ophthalmologist (for eye-related symptoms like uveitis) [8][9]. If local expertise is lacking, ask your doctor about arranging a remote consultation with an autoinflammatory center of excellence.

Preparing Your “Diagnostic Package”

Rare-disease specialists rely heavily on the specific data you provide. To make your first visit as productive as possible, bring an organized folder containing:

  1. The Complete Genetic Report: Do not bring just a summary. Bring the full laboratory printout that includes the specific protein change (e.g., T61I or R92Q), the zygosity (heterozygous vs. homozygous), and the laboratory’s exact classification of the variant [4][10].
  2. A Detailed Flare Diary: Record the exact length of your flares. Specialists look for episodes lasting longer than 7 days to help distinguish TRAPS from other syndromes, though shorter flares can occur [3][11]. Note specific symptoms like eye swelling or migratory muscle pain.
  3. Past Inflammatory Labs: Provide a timeline of your CRP, ESR, and SAA levels. It is particularly helpful to show labs from both “flare” periods and “quiet” periods to see if your inflammation ever fully normalizes [12][8].
  4. Family History: Note any relatives with unexplained recurrent fevers, chronic muscle pain, or kidney issues [13][14].

By providing this structured clinical data, you help your specialist move quickly from investigation to a personalized management plan.

Common questions in this guide

Which specialist should lead my TRAPS care?
A rheumatologist or immunologist who treats systemic autoinflammatory diseases often coordinates TRAPS care. This clinician can help manage flares, oversee IL-1 inhibitor treatment, and arrange referrals to genetics, nephrology, or other specialists when needed.
What records should I bring to my first TRAPS specialist visit?
Bring the complete genetic report, including the TNFRSF1A change, whether it is present in one or both gene copies, and the laboratory’s classification. Also bring a dated flare diary, CRP, ESR, and SAA results from flare and quiet periods, and relevant family history.
How are uncertain TNFRSF1A genetic results used in TRAPS care?
A result labeled a Variant of Uncertain Significance does not provide a clear answer by itself. A genetic counselor, medical geneticist, and autoinflammatory specialist can consider the result together with your symptoms, flare pattern, inflammation tests, and family history when planning next steps.
When should someone with TRAPS see a kidney specialist?
A nephrologist may be helpful if you have protein in your urine, reduced kidney function, high blood pressure, or a high risk of AA amyloidosis. Kidney monitoring is important because AA amyloidosis can damage the kidneys.
What should I ask about IL-1 inhibitor treatment for TRAPS?
Ask which IL-1 inhibitor the clinic usually uses, how insurance approval is handled, and how you will learn to give injections if needed. Also discuss refrigeration, travel storage, and other practical steps for keeping the treatment accessible.
Why should I bring laboratory results from both flare and quiet periods?
Comparing CRP, ESR, and SAA results during flares and symptom-free periods helps the specialist see how much inflammation is present and whether it fully settles. This pattern can support a more individualized TRAPS management plan.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many TRAPS patients are currently managed by this clinic, and do you have a dedicated pathway for monitoring subclinical SAA levels?
  2. 2.If my genetic test shows a Variant of Uncertain Significance, how will you use my clinical symptoms and family history to decide on a treatment plan?
  3. 3.Which IL-1 inhibitor do you typically prescribe for TRAPS, and how do you navigate insurance authorization for these rare-disease medications?
  4. 4.Given my current kidney labs and risk factors, do you recommend a referral to a nephrologist at this time?
  5. 5.Can you help me connect with a genetic counselor to discuss the implications of my diagnosis for my family planning and relatives?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist.

    Romano M, Arici ZS, Piskin D, et al.

    Annals of the rheumatic diseases 2022; (81(7)):907-921 doi:10.1136/annrheumdis-2021-221801.

    PMID: 35623638
  2. 2

    The Added Value of a Multidisciplinary Clinic for Systemic Autoinflammatory Diseases.

    Zinterl C, Costa-Reis P, Esteves IC, et al.

    Journal of multidisciplinary healthcare 2022; (15()):999-1010 doi:10.2147/JMDH.S351546.

    PMID: 35548670
  3. 3

    Biotechnological Agents for Patients With Tumor Necrosis Factor Receptor Associated Periodic Syndrome-Therapeutic Outcome and Predictors of Response: Real-Life Data From the AIDA Network.

    Vitale A, Obici L, Cattalini M, et al.

    Frontiers in medicine 2021; (8()):668173 doi:10.3389/fmed.2021.668173.

    PMID: 34307404
  4. 4

    INSAID Variant Classification and Eurofever Criteria Guide Optimal Treatment Strategy in Patients with TRAPS: Data from the Eurofever Registry.

    Papa R, Lane T, Minden K, et al.

    The journal of allergy and clinical immunology. In practice 2021; (9(2)):783-791.e4 doi:10.1016/j.jaip.2020.10.053.

    PMID: 33181346
  5. 5

    Somatic mosaicism in adult-onset TNF receptor-associated periodic syndrome (TRAPS).

    Kontzias A, Zarabi SK, Calabrese C, et al.

    Molecular genetics & genomic medicine 2019; (7(8)):e791 doi:10.1002/mgg3.791.

    PMID: 31397119
  6. 6

    Tumour necrosis factor receptor-1 associated periodic syndrome (TRAPS)-related AA amyloidosis: a national case series and systematic review.

    Delaleu J, Deshayes S, Rodrigues F, et al.

    Rheumatology (Oxford, England) 2021; (60(12)):5775-5784 doi:10.1093/rheumatology/keab252.

    PMID: 33715002
  7. 7

    Recurrent fever and arthralgia as the presentation of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) in a Chinese girl: a case report and review of the literature.

    Chen Y, Huang X, Zheng S, et al.

    Clinical rheumatology 2018; (37(5)):1433-1438 doi:10.1007/s10067-018-4023-4.

    PMID: 29450850
  8. 8

    Clinical Features at Onset and Genetic Characterization of Pediatric and Adult Patients with TNF-α Receptor-Associated Periodic Syndrome (TRAPS): A Series of 80 Cases from the AIDA Network.

    Gaggiano C, Vitale A, Obici L, et al.

    Mediators of inflammation 2020; (2020()):8562485 doi:10.1155/2020/8562485.

    PMID: 32831641
  9. 9

    The protean ocular involvement in monogenic autoinflammatory diseases: state of the art.

    Bascherini V, Granato C, Lopalco G, et al.

    Clinical rheumatology 2015; (34(7)):1171-80 doi:10.1007/s10067-015-2920-3.

    PMID: 25833143
  10. 10

    Making a diagnosis of periodic fever syndrome: Experience from a single tertiary centre.

    McNaughton P, Willcocks S, Lum SH, et al.

    Journal of paediatrics and child health 2022; (58(3)):404-408 doi:10.1111/jpc.15722.

    PMID: 34499401
  11. 11

    Efficacy of anakinra in an adult patient with recurrent pericarditis and cardiac tamponade as initial manifestations of tumor necrosis factor receptor-associated periodic syndrome due to the R92Q TNFRSF1A variant.

    Camprubí D, Mitjavila F, Arostegui JI, Corbella X

    International journal of rheumatic diseases 2017; (20(4)):510-514 doi:10.1111/1756-185X.13029.

    PMID: 27990755
  12. 12

    Subclinical TRAPS treated with canakinumab.

    Amatruda M, Carucci NS, Fede C, Conti G

    Reumatismo 2021; (73(2)):131-134 doi:10.4081/reumatismo.2021.1406.

    PMID: 34342215
  13. 13

    Molecular and clinical spectrum of four pedigrees of TRAPS in Greece: results from a national referral center.

    Nezos A, Argyropoulou OD, Klinaki E, et al.

    Rheumatology (Oxford, England) 2020; (59(6)):1241-1246 doi:10.1093/rheumatology/kez424.

    PMID: 31562507
  14. 14

    Tumor Necrosis Factor Receptor-Associated Periodic Syndrome (TRAPS) with a New Pathogenic Variant in TNFRSF1A Gene in a Family of the Adult Male with Renal AA Amyloidosis-Diagnostic and Therapeutic Challenge for Clinicians.

    Zegarska J, Wiesik-Szewczyk E, Hryniewiecka E, et al.

    Journal of clinical medicine 2021; (10(3)) doi:10.3390/jcm10030465.

    PMID: 33530412

This page is for informational purposes and does not replace medical advice. A rheumatologist or immunologist with TRAPS expertise should help interpret your genetic results, laboratory trends, and need for specialist referrals.

Get notified when new evidence is published on Tumor necrosis factor receptor 1 associated periodic syndrome.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.